By Victor Abrego The evaluation of non-mutagenic impurities (NMIs) is a critical aspect of pharmaceutical development, ensuring that products are safe for human consumption. While the ICH Q3A and Q3B guidelines establish a general framework, challenges remain in qualifying impurities that are new or at higher concentrations than previously evaluated. How do you evaluate non-mutagenicimpurities and... Read More... "Qualification of Non-Mutagenic Impurities: Modern Strategies and Risk Assessment".
QSAR ANALYTICS© 2026